A double‐blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia.

British Journal of Clinical Pharmacology

Volumn 18, Issue 3, 1984, Pages 461-462

  Champault, G ^a   Patel, JC ^a   Bonnard, AM ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PLANT EXTRACT; SABAL; TESTOSTERONE;

ADVERSE DRUG REACTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG THERAPY; DYSURIA; HEADACHE; HUMAN; INTOXICATION; MALE GENITAL SYSTEM; NERVOUS SYSTEM; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PROSTATE HYPERTROPHY; THERAPY; URINARY TRACT;

CLINICAL TRIALS; DOUBLE-BLIND METHOD; HUMAN; MALE; PLANT EXTRACTS; PROSTATIC HYPERPLASIA;

EID: 0021213498     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1984.tb02491.x     Document Type: Article

References (7)

1. Permixon, a new treatment for benign prostatic hyperplasia, acts directly at the cytosolic androgen receptor in rat prostate.
2. Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate.
3. Endogenous steroid levels in the human prostate from birth to old age: a comparison of normal and diseased tissues.
4. Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of DHT in the hypertrophic prostate of man.
5. Inhibition of androgen metabolism and binding by a liposterolic extract of Serenoa Repens B in human foreskin fibroblasts.
6. Etude pharmacologique et biochimique de l'extrait hexanique de Serenoa Repens B (PA109).
7. The pathogenesis of benign prostatic hyperplasia.